PET-MR Study of Fatty Liver

Status Active, not recruiting

Clinical Trial Summary

This is a pilot, translational study designed to explore the feasibility of molecular imaging with FBA-A20FMDV2, radiolabelled with fluorine-18 ([18F]-FBA-A20FMDV2), in patients with SH and CASH in hepatic metastatic disease. FBA-A20FMDV2, a synthetic peptide derived from the foot and mouth disease virus (FMDV), has been shown pre-clinically to specifically bind to the epithelial specific integrin αvβ6 which is known to be overexpressed in tumours. In this study, we aim to evaluate the uptake of [18F]-FBA-A20FMDV2 ([18F]-IMAFIB) in patients with SH and CASH in CRC hepatic metastatic disease using PET. Up to ten subjects will undergo [18F]-FBA-A20FMDV-PET scanning. An adaptive study design will enable us to determine the optimal imaging protocol for future studies.

Clinical Trial Description

This is a pilot study in two parts that aims to determine the feasibility of conducting PET-MR imaging using [18F]-FBA-A20FMDV2 ([18F]-IMAFIB) and novel PET-MR imaging in patients with SH and CASH in CRC hepatic metastatic disease. A combination of factors will be used to determine the feasibility of [18F]-IMAFIB PET-MR imaging including visual adequacy of the PET-MR image, adequate signal to noise ratio and the ability to evaluate changes in [18F]-IMAFIB uptake and PET-MR parameters. In addition, the operational feasibility of this study will be assessed. Up to 10 patients will be evaluated in this study. The number of patients to be included in this heterogeneous cohort of patients has been based on feasibility considerations taking into account recruitment rates and not on any formal statistical evaluation. An adaptive study design will be used with patients with imaging results being continuously assessed. In the first part 3 patients will be imaged, 2 with severe biopsy proven SH and one with severe CASH. Thereafter, depending on the imaging results, the second part will include up to 7 patients with mild to moderate SH and those with mild to moderate CASH. If there are major changes in the imaging protocol an amendment to the ethics committee will be submitted. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04063826
Study type	Interventional
Source	Imperial College London
Contact
Status	Active, not recruiting
Phase	N/A
Start date	April 10, 2018
Completion date	December 31, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01476995` - Prognostic Indicators as Provided by the EPIC ClearView	N/A
Active, not recruiting	`NCT01246388` - Non-Invasive Evaluation of Fibrosis and Steatosis in Chronic Hepatopathy	N/A
Terminated	`NCT05864391` - A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD7503 in Participants With Suspected NASH.	Phase 1
Completed	`NCT01556113` - Genetic Effect on Omega 3 Fatty Acids for the Treatment of Fatty Liver Disease	N/A
Completed	`NCT00886301` - Fatty Liver and Ectopic Fat in Overweight and Obese Patients	N/A
Completed	`NCT02009592` - Efficacy of Rifaximin on Hepatosteatosis and Steatohepatitis Patients	N/A
Completed	`NCT01645852` - A Phase II Study of the Effect of a Low Calorie Diet on Patients Undergoing Liver Resection	N/A
Completed	`NCT01154985` - Double-Blind, Placebo-Controlled Study of Two Doses of EPA-E in Patients With Non Alcoholic Steatohepatitis (NASH)	Phase 2
Completed	`NCT00512512` - Transoral Endoscopic Liver Biopsy During Laparoscopic Gastric Bypass	N/A
Completed	`NCT03915002` - Integrated Approaches for Identifying Molecular Targets in Liver Disease
Active, not recruiting	`NCT00326482` - Liver Fibrosis in HIV-Infected Patients With Elevated Liver Enzymes on Antiretroviral Therapy
Completed	`NCT00575757` - Relationship of Metabolic Abnormalities to Hepatic Steatosis in HIV	N/A
Recruiting	`NCT05640947` - Endoscopic Ultrasound-guided Large Diameter Lumen-apposing Metal Stent Gastro-gastrostomy for Bypass Reversal in Patients With Roux-en-y Gastric Bypass	N/A
Completed	`NCT01147523` - Effect of Spironolactone and Vitamin E in Patients With Nonalcoholic Fatty Liver Disease	Phase 2
Active, not recruiting	`NCT05946330` - Nutritional Intervention IN Nash NON-ALCOHOLIC (NAFLD).	N/A
Active, not recruiting	`NCT02378259` - Randomized Clinical Trial; Medical vs Bariatric Surgery for Adolescents (13-16 y) With Severe Obesity	N/A
Terminated	`NCT01523639` - A Randomized, Placebo-controlled, Double-blind Phase II Study Evaluating if Glucophage Can Avoid Liver Injury Due to Chemotherapy Associated Steatosis	Phase 2
Recruiting	`NCT00914446` - Identification of Protective and Worsening Steatohepatitis (NASH) Factors	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

PET-MR Study of Fatty Liver — iDOSH

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms